Alvotech (ALVO)
NASDAQ: ALVO · Real-Time Price · USD
4.920
-0.030 (-0.61%)
At close: Jan 16, 2026, 4:00 PM EST
4.950
+0.030 (0.61%)
After-hours: Jan 16, 2026, 6:09 PM EST
Alvotech Revenue
Alvotech had revenue of $113.86M in the quarter ending September 30, 2025, with 10.56% growth. This brings the company's revenue in the last twelve months to $573.35M, up 45.55% year-over-year. In the year 2024, Alvotech had annual revenue of $491.98M with 426.84% growth.
Revenue (ttm)
$573.35M
Revenue Growth
+45.55%
P/S Ratio
2.48
Revenue / Employee
$566,551
Employees
1,012
Market Cap
1.54B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 491.98M | 398.60M | 426.84% |
| Dec 31, 2023 | 93.38M | 8.37M | 9.84% |
| Dec 31, 2022 | 85.02M | 45.33M | 114.23% |
| Dec 31, 2021 | 39.68M | -29.77M | -42.86% |
| Dec 31, 2020 | 69.45M | -13.23M | -16.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ALVO News
- 6 days ago - Bragar Eagel & Squire, P.C. Continues Investigations into Alvotech and Beyond Meat on Behalf of Stockholders and Encourages Investors to Contact the Firm - GlobeNewsWire
- 12 days ago - Correction: Transactions of Managers and Closely Associated Persons - GlobeNewsWire
- 13 days ago - Transactions of Managers and Closely Associated Persons - GlobeNewsWire
- 19 days ago - Alvotech Secures Term Loan Facility of USD 100 Million - GlobeNewsWire
- 21 days ago - Changes in company's own shares - GlobeNewsWire
- 4 weeks ago - Alvotech's Financial Calendar for 2026 - GlobeNewsWire
- 4 weeks ago - Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma - GlobeNewsWire
- 4 weeks ago - Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman - PRNewsWire